Chitosan Interferon-γ Nanogene Therapy for Lung Disease: Modulation of T-Cell and Dendritic Cell Immune Responses

Allergy, Asthma & Clinical Immunology

Shyam S Mohapatra²  Richard Lockey¹  Sumita Behera³  Aruna Behera³  Mukesh Kumar³  Prasanna Jena³  Weidong Zhang³  Gary R Hellermann³  Xiaoyuan Kong³ 

[1]James A. Haley VA Medical Center, Tampa, FL

[2]Division of Allergy and Immunology, Joy McCann Culverhouse Airway Disease Research Center, University of South Florida College of Medicine, Box MDC-19, 12901 Bruce B. Downs Blvd, Tampa, FL 33612

[3]Division of Allergy and Immunology, Culverhouse Airway Disease Research and Nanomedicine Center, University of South Florida College of Medicine, Tampa, FL

关键词: interferon;    asthma;    allergy;   

Others  :  1083804
DOI  :  10.1186/1710-1492-4-3-95

【 授权许可】

   
2008 Canadian Society of Allergy and Clinical Immunology

【 参考文献 】

• [1]Behera AK, Kumar M, Lockey RF, Mohapatra SS: Adenovirus-mediated interferon gamma gene therapy for allergic asthma: involvement of interleukin 12 and STAT4 signaling. Hum Gene Ther 2002, 13:1697-709.
• [2]Monahan PE, Samulski RJ: AAV vectors: is clinical success on the horizon? Gene Ther 2000, 7:24-30.
• [3]Senior K: Adeno-associated virus vectors under scrutiny. Lancet 2002, 359(9313):1216.
• [4]Zaiss AK, Liu Q, Bowen GP, et al.: Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol 2002, 76:4580-90.
• [5]Zhao N, Liu DP, Liang CC: Hot topics in adeno-associated virus as a gene transfer vector. Mol Biotechnol 2001, 19:229-37.
• [6]Cohen AD, Boyer JD, Weiner DB: Modulating the immune response to genetic immunization. FASEB J 1998, 12:1611-26.
• [7]Donnelly JJ, Ulmer JB, Liu MA: DNA vaccines. Dev Biol Stand 1998, 95:43-53.
• [8]Erbacher P, Zou S, Bettinger T, et al.: Chitosan-based vector/DNA complexes for gene delivery: biophysical characteristics and transfection ability. Pharm Res 1998, 15:1332-9.
• [9]Lee KY, Kwon IC, Kim YH, et al.: Preparation of chitosan self-aggregates as a gene delivery system. J Control Release 1998, 51:213-20.
• [10]Leong KW, Mao HQ, Truong-Le VL, et al.: DNA-polycation nanospheres as non-viral gene delivery vehicles. J Control Release 1998, 53:183-93.
• [11]Richardson SC, Kolbe HV, Duncan R: Potential of low molecular mass chitosan as a DNA delivery system: biocompatibility, body distribution and ability to complex and protect DNA. Int J Pharm 1999, 178:231-43.
• [12]Roy K, Mao HQ, Huang SK, Leong KW: Oral gene delivery with chitosan--DNA nanoparticles generate immunologic protection in a murine model of peanut allergy. Nat Med 1999, 5:387-91.
• [13]Nishimura K, Nishimura S, Nishi N, et al.: Immunological activity of chitin and its derivatives. Vaccine 1984, 2:93-9.
• [14]Otterlei M, Varum KM, Ryan L, Espevik T: Characterization of binding and TNF-alpha-inducing ability of chitosans on monocytes: the involvement of CD14. Vaccine 1994, 12:825-32.
• [15]Muzzarelli R, Baldassarre V, Conti F, et al.: Biological activity of chitosan: ultrastructural study. Biomaterials 1988, 9:247-52.
• [16]Pappineau A, Hoover D, Knoor D, Farkas D: Food biotechnol. New York (NY); Marcel Dekker 1991, 5:45-7.
• [17]Aspden TJ, Mason JD, Jones NS, et al.: Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. J Pharm Sci 1997, 86:509-13.
• [18]Bodmeier R, Chen HG, Paeratakul O: A novel approach to the oral delivery of micro- or nanoparticles. Pharm Res 1989, 6:413-7.
• [19]Illum L, Farraj NF, Davis SS: Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res 1994, 11:1186-9.
• [20]Miyazaki S, Nakayama A, Oda M, et al.: Chitosan and sodium alginate based bioadhesive tablets for intraoral drug delivery. Biol Pharm Bull 1994, 17:745-7.
• [21]Tozaki H, Komoike J, Tada C, et al.: Chitosan capsules for colon-specific drug delivery: improvement of insulin absorption from the rat colon. J Pharm Sci 1997, 86:1016-21.
• [22]Artursson P, Lindmark T, Davis SS, Illum L: Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res 1994, 11:1358-61.
• [23]Coyle AJ, Tsuyuki S, Bertrand C, et al.: Mice lacking the IFN-gamma receptor have impaired ability to resolve a lung eosinophilic inflammatory response associated with a prolonged capacity of T cells to exhibit a Th2 cytokine profile. J Immunol 1996, 156:2680-5.
• [24]Romagnani S: Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994, 12:227-57.
• [25]Wenner CA, Guler ML, Macatonia SE, et al.: Roles of IFN-gamma and IFN-alpha in IL-12-induced T helper cell-1 development. J Immunol 1996, 156:1442-7.
• [26]Szeto C, Gillespie KM, Mathieson PW: Levamisole induces interleukin-18 and shifts type 1/type 2 cytokine balance. Immunology 2000, 100:217-24.
• [27]Gao Y, Chenping Z, Lin XP: [Aerosolized recombinant interferon-gamma prevent antigen-induced eosinophil recruitment in guinea pig trachea]. Zhonghua Jie He He Hu Xi Za Zhi 1997, 20:287-90.
• [28]Boraschi D, Censini S, Bartalini M, et al.: Interferons inhibit LTC4 production in murine macrophages. J Immunol 1987, 138:4341-6.
• [29]Chen H, Munakata M, Amishima M, et al.: Gamma-interferon modifies guinea pig airway functions in vitro. Eur Respir J 1994, 7:74-80.
• [30]Pouw Kraan TC, Boeije LC, de Groot ER, et al.: Reduced production of IL-12 and IL-12-dependent IFN-gamma release in patients with allergic asthma. J Immunol 1997, 158:5560-5.
• [31]Daines MO, Hershey GK: A novel mechanism by which interferon-gamma can regulate interleukin (IL)-13 responses. Evidence for intracellular stores of IL-13 receptor alpha-2 and their rapid mobilization by interferon-gamma. J Biol Chem 2002, 277:10387-93.
• [32]Ford JG, Rennick D, Donaldson DD, et al.: IL-13 and IFN-gamma: interactions in lung inflammation. J Immunol 2001, 167:1769-77.
• [33]Krasnowska M, Medrala W, Malolepszy J, Krasnowski R: Effect of recombinant IFN-gamma on IgE-dependent leukotriene generation by peripheral blood leukocytes in patients with pollinosis and asthma. Arch Immunol Ther Exp (Warsz) 2000, 48:287-92.
• [34]Pierkes M, Bellinghausen I, Hultsch T, et al.: Decreased release of histamine and sulfidoleukotrienes by human peripheral blood leukocytes after wasp venom immunotherapy is partially due to induction of IL-10 and IFN-gamma production of T cells. J Allergy Clin Immunol 1999, 103(2 Pt 1):326-32.
• [35]Gurujeyalakshmi G, Giri SN: Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression. Exp Lung Res 1995, 21:791-808.
• [36]Cohen J: IL-12 deaths: explanation and a puzzle. Science 1995, 270:908.
• [37]Mohapatra SS: IL-12 possibilities. Science 1995, 269:1499.
• [38]Hogan SP, Foster PS, Tan X, Ramsay AJ: Mucosal IL-12 gene delivery inhibits allergic airways disease and restores local antiviral immunity. Eur J Immunol 1998, 28:413-23.
• [39]Murray HW: Current and future clinical applications of interferon-gamma in host antimicrobial defense. Intensive Care Med 1996, 22(Suppl 4):S456-61.
• [40]Sur S, Lam J, Bouchard P, et al.: Immunomodulatory effects of IL-12 on allergic lung inflammation depend on timing of doses. J Immunol 1996, 157:4173-80.
• [41]Dow SW, Schwarze J, Heath TD, et al.: Systemic and local interferon gamma gene delivery to the lungs for treatment of allergen-induced airway hyperresponsiveness in mice. Hum Gene Ther 1999, 10:1905-14.
• [42]Li XM, Chopra RK, Chou TY, et al.: Mucosal IFN-gamma gene transfer inhibits pulmonary allergic responses in mice. J Immunol 1996, 157:3216-9.
• [43]Okubo T, Hagiwara E, Ohno S, et al.: Administration of an IL-12-encoding DNA plasmid prevents the development of chronic graft-versus-host disease (GVHD). J Immunol 1999, 162:4013-7.
• [44]Tovey MG, Maury C: Oromucosal interferon therapy: marked antiviral and antitumor activity. J Interferon Cytokine Res 1999, 19:145-55.
• [45]Kumar M, Behera AK, Lockey RF, et al.: Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Hum Gene Ther 2002, 13:1415-25.
• [46]Kumar M, Kong X, Behera AK, et al.: Chitosan IFN-gamma-pDNA nanoparticle (CIN) therapy for allergic asthma. Genet Vaccines Ther 2003, 1:3. BioMed Central Full Text
• [47]Laliotou B, Duncan L, Dick AD: Intranasal administration of retinal antigens induces transient T cell activation and apoptosis within drainage lymph nodes but not spleen. J Autoimmun 1999, 12:145-55.
• [48]Badovinac VP, Tvinnereim AR, Harty JT: Regulation of antigen-specific CD8+ T cell homeostasis by perforin and interferon-gamma. Science 2000, 290:1354-58.
• [49]Lohman BL, Welsh RM: Apoptotic regulation of T cells and absence of immune deficiency in virus-infected gamma interferon receptor knockout mice. J Virol 1998, 72:7815-21.